Monopar Therapeutics (MNPR) Expected to Announce Earnings on Friday

Key Points

• Monopar Therapeutics is scheduled to release its earnings report on Friday, August 8th, with analysts predicting a loss of ($0.47) per share for the quarter.
• In its previous earnings report on May 13th, the company exceeded expectations by reporting a loss of ($0.38) EPS, beating the consensus estimate of ($0.65).
• CEO Chandler Robinson and Director Christopher M. Starr recently sold shares of Monopar, indicating a significant decrease in their holdings.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Monopar Therapeutics to post earnings of ($0.47) per share for the quarter.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.27. On average, analysts expect Monopar Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Monopar Therapeutics Stock Performance

MNPR traded down $0.49 on Friday, hitting $40.69. 35,807 shares of the company were exchanged, compared to its average volume of 34,661. The business's fifty day moving average is $37.32 and its 200 day moving average is $37.49. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The firm has a market capitalization of $249.02 million, a P/E ratio of -11.69 and a beta of 1.05.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Monopar Therapeutics in a research report on Monday, July 7th. They set an "overweight" rating and a $74.00 target price on the stock. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Chardan Capital began coverage on shares of Monopar Therapeutics in a research report on Monday, June 23rd. They issued a "buy" rating and a $60.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Monopar Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $60.00.

Insider Activity

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the sale, the director directly owned 11,486 shares in the company, valued at $459,440. This represents a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the chief executive officer owned 73,472 shares in the company, valued at $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock worth $1,700,160 over the last ninety days. 20.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monopar Therapeutics

A hedge fund recently bought a new stake in Monopar Therapeutics stock. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,480 shares of the company's stock, valued at approximately $673,000. Goldman Sachs Group Inc. owned 0.30% of Monopar Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.